Good afternoon, ladies and gentlemen, and welcome to the ADC Therapeutics corporate webcast and conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during the call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, November 4th, 2026. I would now like to turn the conference over to Nicole Riley. Thank you, operator. Today, we issued a press release announcing details on our presence at the upcoming American Society of Hematology meeting. This release and the slides we will use in today's presentation are available on the Investor section of the ADC Therapeutics website. I am joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss key business updates and recent highlights, followed by our Chief Medical Officer, Mohamed Zaki, who will provide an overview of key ZYNLONTA abstracts accepted for presentation at the 68th ASH Annual Meeting taking place December 12th to 15th. Lastly, our Chief Financial Officer, Pepe Carmona, who will share details on our strategic financial restructuring and provide preliminary financials for Q3 2026. We will then open the call to questions. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain known and unknown risks and uncertainties, and actual results, performance, and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10-K, 10-Q, and eight-K. ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events, or circumstances, except as required by law. The company cautions investors not to place undue reliance on these forward-looking statements. Today's conference call includes preliminary revenue and cash and cash equivalents figures, which reflects the company's estimated financial results. The company's actual financial results have not yet been finalized by management and are subject to change. Accordingly, investors should not place undue reliance on these preliminary financial results. I will now turn the call over to our CEO, Ameet Mallik. Ameet? Thank you, Nicole. Today, we will share an update on our upcoming ASH presence, as well as key business updates and recent highlights. Before we get into these details, I want to frame our key value drivers, which are supported by our strong balance sheet. Building on our approved indication for ZYNLONTA in third-line plus DLBCL, we have potential best-in-class data, which we will share with you today, for both the LOTIS-7 combination in second-line plus DLBCL, as well as monotherapy in second-line plus marginal zone lymphoma. The recently announced financial restructuring and PIPE give us the balance sheet and runway to pursue those opportunities while increasing strategic optionality. Beginning now with ASH, we are pleased to have multiple ZYNLONTA data abstracts accepted for presentation in December. This includes five oral presentations across DLBCL and indolent lymphomas, as well as multiple posters. Importantly, updated phase I-B LOTIS-7 data will be featured in an oral presentation. As detailed in the abstract posted today, the combination of ZYNLONTA plus glofitamab demonstrated deep and durable responses. Across the 97 efficacy-evaluable for relapse or refractory DLBCL patients, we observed an 88.7% overall response rate and a 75.3% complete response rate. Marginal zone lymphoma data will also be shared via an oral presentation with impressive response rates, as seen by the 93% overall response rate and 74.4% complete response rate with ZYNLONTA in the multi-site phase II IIT. Additional oral presentations will feature full phase III LOTIS-5 results, as well as investigator-initiated studies in mantle cell lymphoma and Waldenström disease. Mohamed will share additional details on the data included in the abstract for each of these. Moving now to our corporate updates, in early October, we announced a comprehensive strategic financial restructuring designed to strengthen our balance sheet, reduce leverage, and increase strategic optionality to maximize shareholder value while extending the expected cash runway into 2029. This included securing new equity financing, restructuring the HealthCare Royalty agreement, and reducing the outstanding loan principal. From a business perspective, we are pleased to share that ZYNLONTA's commercial performance in the third quarter of 2026 continued to be strong, with net product revenues expected to be approximately $21 million for this period. As such, we remain confident in the role ZYNLONTA continues to play as a differentiated single-agent treatment option for third-line plus DLBCL patients. I'd now like to turn the call over to Mohamed Zaki, our Chief Medical Officer, to share more about the ZYNLONTA ASH abstracts accepted for oral presentations. Mohamed? Thank you, Ameet. As noted, ZYNLONTA data at ASH will be included in five oral presentations, as well as multiple poster presentations over the course of the meeting. These data add to the growing body of evidence in the support of the potential for ZYNLONTA in DLBCL and indolent lymphomas. Most important among these oral presentations is LOTIS-7. In this phase I-B trial, updated results with ZYNLONTA plus glofitamab continue to demonstrate the most compelling combination data generated to date in second-line DLBCL, including in difficult-to-treat patient populations. Per the abstract, as of the June 15, 2026 data cut-off, among 97 efficacy-evaluable patients, the overall response rate was 88.7%, and the complete response rate was 75.3%, with 28 patients converting from stable disease or partial response to complete response over time. In patients with primary refractory disease, overall response rate was 78.4%, and the complete response rate was 64.7%. Among patients previously treated with CAR-T therapy, overall response rate was 74.1%, and the complete response rate was 63%. This is especially meaningful in these difficult-to-treat patients where there remains high unmet need. At a median follow-up of 10.35 months, median duration of response, duration of complete response, and progression-free survival had not been reached. The 12-month duration of complete response was 79%. Also of note, in an exploratory MRD analysis of 12 patients who achieved a complete response, six had undetectable MRD as early as cycle two, day one, and 11 patients had undetectable MRD at the end of treatment. The emerging data continues to demonstrate the best-in-class potential for ZYNLONTA when combined with glofitamab in treating relapsed/refractory DLBCL. From a safety perspective, this study continues to show a manageable safety profile. Of note, consistent with other glofitamab trials, the protocol for LOTIS-7 recommends anti-infective prophylaxis treatment. The combination was generally well tolerated, and the type of treatment-emergent adverse events observed were generally consistent with the known safety profiles of each drug separately. It is important to consider the profile and management of cytokine release syndrome and ICANS when using bispecific therapies. By dosing ZYNLONTA prior to glofitamab, we believe that this dosing schedule can debulk the tumor and lower CRS rates and grades. Per the abstract data, cytokine release syndrome occurred in 32% of treated patients, all of which were grade 1 or 2, except one grade 3. This continues to be lower compared to the glofitamab monotherapy label. No grade 3 or higher ICANS events were observed. Three grade 5 treatment-emergent adverse events were reported, with one due to sepsis and two due to capillary leak syndrome. As noted in the abstract, the study authors conclude that these efficacy and safety findings support further investigation of ZYNLONTA plus glofitamab in a phase III study, which we are actively pursuing. We have submitted a briefing book to the FDA for an upcoming meeting and will share details on the planned study design once we have aligned with the FDA. Next, looking at the investigator-initiated multicenter phase II study with fixed-duration ZYNLONTA in patients with relapsed or refractory marginal zone lymphoma, ZYNLONTA continues to demonstrate deep response rates and encouraging durability. As of the July 1, 2026 data cut-off, among the 43 efficacy-evaluable patients, overall response rate was 93% and complete response rate was 74.4%. At a median follow-up of 23.2 months, the estimated two-year PFS rate was 90.8%, and the duration of response at 24 months was 90.9%. Based on this, the study authors concluded that single-agent ZYNLONTA demonstrated clinically meaningful activity with robust and durable complete responses in relapsed or refractory MZL and characterized the responses as comparable with those reported for recently approved CAR-T therapy. From a safety perspective, the data continues to suggest a manageable safety profile that is generally consistent with the known profile of ZYNLONTA. All 46 treated patients experienced expected adverse events, most commonly grade 1 or 2. Grade 3 and grade 4 adverse events were observed in 23 and five patients, respectively. Turning now to LOTIS-5, our confirmatory study for ZYNLONTA in combination with rituximab versus R-GemOx in patients with second-line plus DLBCL, which recently read out. Full results from this randomized phase III study of 420 patients demonstrated a statistically significant improvement in the primary endpoint of PFS with ZYNLONTA plus rituximab compared with R-GemOx. As of the data cutoff of February 16, 2026, median PFS by independent review was 6.14 months with ZYNLONTA plus rituximab versus 4.73 months with R-GemOx, with a hazard ratio of 0.73. Overall response rate was 58.1% versus 45.2%, and complete response rate was 39.5% versus 26.7%, respectively. Median duration of complete response was 16.82 months versus 12.25 months. At 24 months, 48.5% versus 16.7% of patients who achieved complete response remained in complete response. No statistically significant difference in overall survival was observed between treatment arms. From a safety perspective, within the protocol-defined 105-day treatment-emergent adverse events reporting window, grade 3 or higher events occurred in 74% of patients with ZYNLONTA plus rituximab versus 76.1% of patients with R-GemOx, and grade 5 events occurred in 13.2% versus 4.6%, respectively. Using a standard 30-day post-treatment window, grade 5 events occurred in 1.5% of patients in the ZYNLONTA plus rituximab arm versus 3% in the R-GemOx arm. Of note, a meaningful decrease in grade 5 events was observed in ZYNLONTA plus rituximab arm in patients receiving prophylaxis. Another oral presentation at ASH will cover an IIT in relapsed/refractory mantle cell lymphoma. Here, initial data show promising ZYNLONTA activity as consolidation therapy after rituximab plus bendamustine and cytarabine, known as R-BAC, which is primarily considered a salvage regimen with limited durability. Per the abstract, the phase II study of ZYNLONTA consolidation following short course of R-BAC met its primary endpoint of PFS at 12 months. In the 49 patients with BTKi-exposed relapsed/refractory mantle cell lymphoma, a 12-month PFS rate of 70% and manageable toxicity was observed. Investigators concluded the findings support ZYNLONTA consolidation following short course of R-BAC as a promising strategy for BTKi-exposed relapsed/refractory mantle cell lymphoma. These findings also support further evaluation of ZYNLONTA-based combinations in mantle cell lymphoma. Finally, updated data from the phase II IIT of 20 heavily pretreated patients with relapsed/refractory Waldenström's showed ZYNLONTA demonstrated a 90% overall response rate, including a 60% very good partial response/complete response rate, meeting the study's primary endpoint. These data expand upon the previously presented 14-patient update shared at ASH 2025, which formed the basis for the recent addition of this regimen to NCCN guidelines. Per the abstract, investigators concluded that ZYNLONTA demonstrated a high overall response rate despite the presence of high-risk mutations, and the findings support its use as a novel time-limited therapy for patients with relapsed/refractory Waldenström's, including those with high-risk disease. As you can see, the data from this oral presentation, as well as multiple ZYNLONTA posters at ASH, add to the growing body of evidence of potential role ZYNLONTA can play across a broad range of B-cell malignancies. Importantly, we are most excited about the emerging LOTIS-7 and MZL data, both of which are highly differentiated and continue to show deep and durable efficacy with manageable safety. With that, I would like to turn the call over to Pepe Carmona, our CFO. Pepe? Thank you, Mohamed. As Hamid noted, this past quarter, we undertook a strategic financial restructuring that strengthened our balance sheet, supporting continued investment in ZYNLONTA. This transaction strengthened our capital structure, reduced leverage, and enhanced strategic optionality, and extended our expected cash runway into 2029. In October 2026, we announced an $86.6 million private investment in public equity financing with participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. We also amended our HealthCare Royalty financing agreement to eliminate a $150 million change-of-control payment. In addition, we priced the existing warrants owned by HCR at par value, and we amended our senior secured loan agreement to reduce outstanding principal to $50 million and eliminate scheduled principal amortization with a bullet payment in August 2029. We significantly reduced the exposure to all stakeholders by fully removing the minimum liquidity covenant and significantly reducing the minimum revenue covenant to $65 million flat. Finally, we have been working closely with Tanabe to ensure successful regulatory filing for ZYNLONTA in Japan, and now, with the sublicense agreement to Nippon Shinyaku, we will be working closely with them to ensure a successful launch. Through the combination of excellent data in Japan and now a commercial partner with a strong footprint in hematology and oncology, we believe Japan represents a significant opportunity for ZYNLONTA. Based on our contract with Tanabe, as we realize potential milestones due upon acceptance of filing and first commercial sales, we expect this will further strengthen our balance sheet and potentially further extend our cash runway in 2029. Today, we are providing flash financials for the third quarter, and we will file a 10-Q and press release on November 9th and will not hold an earnings call at that time. At this point, I would like to share a summary of the key metrics for the quarter. Net revenue from sales of ZYNLONTA were estimated to be approximately $21 million and $6 million for the quarter and year-to-date, respectively. The increase during these periods was primarily attributable to an increase in sales volume. We ended Q3 with an estimated cash balance of approximately $189 million and an adjusted cash balance of $196 million on a pro forma basis, giving effect to the estimated net cash proceeds from the recent PIPE offering and the partial principal prepayment on the senior secured term loan, as well as exit fees and interest, which closed on October 22nd, 2026. With that, I will turn the call back over to Ameet. Ameet? Thank you, Pepe. As we seek to expand ZYNLONTA from its current third-line plus DLBCL treatment setting into earlier line DLBCL and indolent lymphomas, we have multiple catalysts between now and the end of 2027 across our trials. As shared today, we are most excited about the path forward with the combination of ZYNLONTA plus glofitamab in second-line plus DLBCL and ZYNLONTA as monotherapy in MZL. For LOTIS-7, we are seeking publication of the data, and following that, plan to submit for compendia for potential inclusion starting in the first half of 2027. In addition, based on this potentially practice-changing LOTIS-7 data, we plan to pursue a phase III trial for the combination of ZYNLONTA plus glofitamab. Moving forward, we plan to work closely with the FDA to determine the best path forward to achieve full approval and advance ZYNLONTA combinations into earlier lines of therapy in DLBCL. With marginal zone lymphoma, we intend to submit for breakthrough designation and evaluate regulatory pathways, as well as pursue potential compendia inclusion in 2027. We remain confident that ZYNLONTA will continue to play a meaningful role for patients with B-cell malignancies within its currently approved third-line plus DLBCL setting. To close, we are pleased by the commercial performance and the role that ZYNLONTA monotherapy continues to play in third-line plus DLBCL. We look forward to presentation of data from LOTIS-7 and marginal zone lymphoma at ASH, with publication and potential compendia inclusion to follow. In parallel, we are actively pursuing the regulatory path forward for both. Taken all together, we believe we can grow ZYNLONTA beginning in 2027 as we work to make a meaningful difference in the lives of many more patients with B-cell malignancies. We can now open the line for questions. Operator? Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press star followed by the one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star followed by the two. If you are using a speakerphone, please lift the handset first before pressing any keys. Our first question is from Maury Raycroft with Jefferies. Hi. Congrats on the data update, and thanks for taking my questions. First one, just a quick one on the 75.3% CR rate in the ASH abstract. That is investigator-assessed. Wondering if you have the central IRC-assessed response rate to compare against benchmarks, and if so, are you going to share that at ASH, and how much concordance are you seeing between these two measures? Yeah, thanks, Maury. Great question. The 75% was investigator assessed. We haven't reported any central review. There will be further data at ASH, but not including central review. That hasn't been completed for the whole study. Got it. Okay. I guess the follow-up is just with the amount of follow-up data that you have in the abstract being about 10 months, how should we think about CR durability relative to T-cell engagers as follow-up matures? How much additional follow-up data and what other measures should we expect at ASH? Will you show 18-month duration of complete response rate data and PFS landmark data there as well? Yeah, we can't say what we're going to show, but I can tell you that we will have a more comprehensive update, obviously, than the abstract that we shared today. We also may present a more recent data cut than the abstract, but that depends on whether the journal we submitted the manuscript to is amenable to a mid-review data update. But you will definitely see more data. I think one thing I just want to point out to you, Maury, is in addition to the 75% complete response rate, you probably noticed the duration of CR is at 79%. Both of those numbers, I think we think, if they continue to be maintained in a larger study, have the chance to be really best in class for any bispecific combination. Yeah. Makes sense. Okay. Well, thanks for taking my questions. Thank you very much. As a reminder, if you have a question, please press star then one. We have our next question from Eric Schmidt with Cantor Fitzgerald. Yeah, Mike, congrats on the data as well. Maybe first just a couple of questions around the publication and compendia listing strategy. I want to make sure I understand it properly. So first, in terms of publication, you are expecting a concurrent publication in a journal alongside the ASH conference. Is that correct? We should assume that is the ASH journal? Yes. That is the plan, to have concomitant publication at the same time as the, same day as the presentation of the data at ASH. Thanks, Ameet. In terms of the compendia listing, should you be able to secure that in the first part of next year, what can you do operationally to monetize that? Obviously, you can't in any way promote off-label, but there must be things you can do from a medical science liaison perspective or other corporate initiatives to get that publication and data awareness out to potential users. Yeah, as you said, I mean, we won't promote this off-label, obviously. But through our medical affairs team, obviously when we get requests for data, when there's a scientific exchange, we will of course share the data, answer any questions that people have. We have a pretty robust medical affairs team. We do educational programs with these sponsors as well across the disease areas. I think there's a number of ways to educate and ensure that we're having good scientific exchange on the data with the physicians, of course, in the best interest of patients. My last question is with regard to your upcoming FDA meeting on a confirmatory phase III study for the LOTIS-7 results. Will Roche be part of that meeting, and how should we be thinking about Roche's involvement in a potential pivotal study? Yeah, I'd say we have had a very good collaboration with Roche. Also, in terms of we've already submitted the briefing book for that meeting. They definitely gave us a lot of great input and helped to partner with us on the design, on the briefing book. We believe that we will continue to collaborate with them very strongly on this study going forward. In terms of the actual meeting, they will not be at the meeting. We plan to do the meeting, but we're coordinating quite a bit in advance between the companies. Okay. Thank you very much. Thank you very much. We have no further questions. I will now turn the call over to Ameet Mallik for closing remarks. Well, I want to thank you all for joining our call today and for your continued support. We look forward to keeping you updated on our progress. Operator, you may now end the call. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.